Skip to main content
Article thumbnail
Location of Repository

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen

By M. A. Arias, A Loxley, C Eatmon, G Van Roey, D Fairhurst, M Mitchnick, Philip Dash, T Cole, F Wegmann, Q Sattentau and R Shattock


Induction of humoral responses to HIV at mucosal compartments without inflammation is important for vaccine design. We developed charged wax nanoparticles that efficiently adsorb protein antigens and are internalized by DC in the absence of inflammation. HIV-gp140-adsorbed nanoparticles induced stronger in vitro T-cell proliferation responses than antigen alone. Such responses were greatly enhanced when antigen was co-adsorbed with TLR ligands. Immunogenicity studies in mice showed that intradermal vaccination with HIV-gp140 antigen-adsorbed nanoparticles induced high levels of specific IgG. Importantly, intranasal immunization with HIV-gp140-adsorbed nanoparticles greatly enhanced serum and vaginal IgG and IgA responses. Our results show that HIV-gp140-carrying wax nanoparticles can induce strong cellular/humoral immune responses without inflammation and may be of potential use as effective mucosal adjuvants for HIV vaccine candidates

Publisher: Elsevier
Year: 2011
OAI identifier:

Suggested articles


  1. (1999). A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm Res
  2. (2007). Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1 2. Blood doi
  3. (2005). Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen. Vaccine
  4. (1997). Activation of human dendritic cells following infection with Mycobacterium tuberculosis.
  5. (2004). Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res doi
  6. (2008). Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. doi
  7. (2005). An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. doi
  8. (2004). Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.
  9. (2000). Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. doi
  10. (2004). Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opin Biol Ther
  11. (2008). Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.
  12. (2002). Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. doi
  13. (2009). Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine
  14. (2006). Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology
  15. (2000). Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch
  16. (2003). HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japanliposome induces antigen-specific CTLs and neutralizing antibody responses.
  17. (2009). HIV vaccine development: Lessons from the past, informing the future. IDrugs
  18. (2003). Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles.
  19. (2008). Improving defences at the portal of HIV entry: mucosal and innate immunity. PLoS Med
  20. (2009). Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration. Vaccine doi
  21. (2007). Induction of potent CD8+ Tcell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol doi
  22. (2005). Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. doi
  23. (2006). Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol Lett doi
  24. (2003). Liposomal delivery of antigen to human dendritic cells. Vaccine
  25. (2005). Mucosal immunity and vaccines.
  26. (2003). Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
  27. (2009). Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev
  28. (2008). Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses doi
  29. (2009). New horizons in adjuvants for vaccine development. Trends Immunol
  30. (1999). New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview.
  31. (2000). Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release
  32. (2005). PLA-PEG particles as nasal protein carriers: the influence of the particle size. doi
  33. (2003). Plasma-cell homing. Nat Rev Immunol
  34. (2006). Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv doi
  35. (2006). Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol
  36. (2002). Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
  37. (2008). Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS
  38. (2006). Stable cationic microparticles for enhanced model antigen delivery to dendritic cells.
  39. (2007). Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity.
  40. (1997). The immunopathology of M cells.
  41. (2005). Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials
  42. (2009). Toll-like receptors--sentries in the B-cell response. Immunology doi
  43. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin.
  44. (2000). Transport of drugs from the nasal cavity to the central nervous system. doi
  45. Transport of nanoparticles across the rat nasal mucosa.
  46. (2009). Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.
  47. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
  48. (2010). Vaccine adjuvants: a priority for vaccine research. Vaccine

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.